PharMerica Co. (NYSE:PMC) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Monday, July 31st.
Other analysts have also issued research reports about the company. Zacks Investment Research lowered PharMerica from a “buy” rating to a “hold” rating in a research note on Friday, June 23rd. ValuEngine downgraded PharMerica from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $28.83.
PharMerica (NYSE PMC) traded down 0.17% on Monday, hitting $29.05. The stock had a trading volume of 346,427 shares. PharMerica has a one year low of $19.20 and a one year high of $29.10. The stock has a market cap of $904.07 million, a price-to-earnings ratio of 39.36 and a beta of 0.92. The stock’s 50 day moving average is $26.52 and its 200 day moving average is $24.91.
PharMerica (NYSE:PMC) last posted its earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.47. The company had revenue of $592 million for the quarter, compared to analyst estimates of $592.96 million. PharMerica had a return on equity of 3.41% and a net margin of 0.79%. PharMerica’s revenue was up 13.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.47 earnings per share. Analysts anticipate that PharMerica will post $1.92 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “PharMerica Co. (NYSE:PMC) Downgraded to Sell at BidaskClub” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/11/pharmerica-corporation-nysepmc-stock-rating-lowered-by-bidaskclub-updated.html.
A number of large investors have recently modified their holdings of PMC. BlackRock Inc. raised its position in shares of PharMerica by 51,604.4% in the first quarter. BlackRock Inc. now owns 3,975,551 shares of the company’s stock valued at $93,027,000 after buying an additional 3,967,862 shares during the last quarter. Vanguard Group Inc. raised its position in PharMerica by 5.5% in the second quarter. Vanguard Group Inc. now owns 1,649,704 shares of the company’s stock worth $43,305,000 after buying an additional 85,838 shares in the last quarter. Boston Partners raised its position in PharMerica by 10.7% in the second quarter. Boston Partners now owns 1,376,287 shares of the company’s stock worth $36,127,000 after buying an additional 133,339 shares in the last quarter. Victory Capital Management Inc. raised its position in PharMerica by 40.1% in the second quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock worth $33,971,000 after buying an additional 370,266 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its stake in shares of PharMerica by 61.3% in the first quarter. Nuveen Asset Management LLC now owns 863,975 shares of the company’s stock valued at $20,217,000 after buying an additional 328,257 shares during the last quarter. Hedge funds and other institutional investors own 92.84% of the company’s stock.
PharMerica Company Profile
What are top analysts saying about PharMerica Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PharMerica Co. and related companies.